Showing results (201-210 of 268) with videos related to

Sort By:
Pageof 27
Frontiers in Medicine|September 11, 2024
Seeing the primary tumor because of all the trees: Cancer type prediction on low-dimensional dataJulia Gehrmann, Devina Johanna Soenarto, Kevin Hidayat, et al.
BMC Cancer|January 10, 2019
HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinomaPatrick Sven Plum, Florian Gebauer, Max Krämer, et al.
BMC Cancer|June 24, 2020
Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomasJan Rehkaemper, Michael Korenkov, Alexander Quaas, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 24, 2024
Correlation of primary tumor volume and histopathologic response following neoadjuvant treatment of esophageal adenocarcinomaJohannes Bremm, Stefanie Brunner, Erkan Celik, et al.
European Journal of Haematology|October 12, 2016
Economic evaluation of chronic lymphocytic leukemia from a hospital management perspectiveFlorian Kron, Nadine Kutsch, Anna Kostenko, et al.
Pharmacogenetics and Genomics|January 20, 2010
Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbetaR therapySabine Classen, Christine Muth, Svenja Debey-Pascher, et al.
BMC Gastroenterology|February 6, 2019
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinomaAlexander Quaas, Carina Heydt, Dirk Waldschmidt, et al.
Journal of Translational Medicine|August 17, 2023
The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosisAdrian Georg Simon, Su Ir Lyu, Mark Laible, et al.
Investigational New Drugs|November 11, 2019
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C Bendell, Helge G Bischoff, Jimmy Hwang, et al.
Cancer Immunology, Immunotherapy : CII|January 22, 2020
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinomaSvenja Wagener-Ryczek, Max Schoemmel, Max Kraemer, et al.
Pageof 27